Losulazine

Synonyms: 洛苏拉嗪
Losulazine 是一种具有口服活性的抗高血压药物,可调控酸性磷酸酶 (acid phosphatase)、3β-羟类固醇脱氢酶及 17β-羟类固醇脱氢酶 (17β-HSD) 的活性,并可用于高血压的相关研究。
产品编号: MS-A00127 纯度: 98.83% CAS No.: 72141-57-2 分子式: C27H22F4N4O3S 分子量: 558.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

Losulazine 是一种具有口服活性的抗高血压药物,可调控酸性磷酸酶 (acid phosphatase)、3β-羟类固醇脱氢酶及 17β-羟类固醇脱氢酶 (17β-HSD) 的活性,并可用于高血压的相关研究。

生物实验数据

生物活性 Losulazine is an orally active antihypertensive drug that modulates the activities of acid phosphatase, 3β-hydroxysteroid dehydrogenase, and 17β-hydroxysteroid dehydrogenase (17β-HSD), and can be used in research related to hypertension.
体内研究
(In Vivo)

Losulazine (1-5 mg/kg;腹腔注射;每日给药;连续 13 天) 对成年雄性 Wistar 大鼠的睾丸类固醇生成及附属性腺功能呈剂量依赖性双相作用。
Losulazine (4-32 mg/kg;口服;每日给药;持续 1 年) 在雄性 Sprague-Dawley 大鼠中,可诱导剂量依赖性的可逆性生育力下降、剂量依赖性的体重增长和食物消耗量降低、与剂量无关的轻微至轻度睾丸损伤,以及相对脏器重量增加。
Losulazine (10 mg/kg;口服;每日给药,持续 15-27 天,单次剂量) 通过下丘脑儿茶酚胺耗竭和随后的高催乳素血症,导致雌性 Sprague-Dawley 大鼠完全无发情。
Losulazine (2-8 mg/kg;口服;每日给药) 呈剂量依赖性地损害 Sprague-Dawley 大鼠的生育能力与生殖功能。
Losulazine (2.5-10 mg/kg;腹腔注射;单次给药) 可使大鼠血脑屏障外的脑区和垂体区儿茶酚胺显著且持续耗竭,同时使血脑屏障保护区域的多巴胺出现轻微且短暂的降低,并短暂升高血浆催乳素和 α-黑素细胞刺激素浓度。
Losulazine (2.5 mg/kg;腹腔注射;单次给药;每日一次;连续 12 天) 可导致雌性大鼠发情周期紊乱,在无血脑屏障的脑区和垂体区域持续耗竭儿茶酚胺且无耐受性,同时在纹状体产生累积性多巴胺耗竭作用,但对中枢 5-羟色胺能神经元无影响。
Losulazine 可通过调节交感神经活性在清醒猴中发挥降压作用,且不会引发直立性低血压。

Animal Model: Wistar rats (adult male, 120-140 days old, 145-170 g)
Dosage: 1; 2; 5 mg/kg
Administration: i.p.; daily; 13 days
Result: Significantly increased relative weights of total prostate, ventral prostate, and seminal vesicles at all doses.
Significantly increased relative coagulating gland weight only at 2 mg/kg.
Caused no significant changes in relative testes or epididymis weights.
Significantly increased testicular 3β-hydroxysteroid dehydrogenase (HSD) and 17β-HSD activity, while reducing testicular cholesterol content.
Significantly increased testicular acid phosphatase activity, ventral prostate acid phosphatase activity, and fructose content in seminal vesicles at 1 and 2 mg/kg.
Significantly reduced testicular acid phosphatase activity, and fructose content in seminal vesicles at 5 mg/kg.
Animal Model: Sprague-Dawley rats (male, 220-358 g)
Dosage: 4; 8; 16; 32 mg/kg
Administration: p.o.; daily; 1 year or 30 weeks
Result: Induced dosage-dependent ptosis, somnolence, fecal softening/decreased food consumption.
Caused statistically significant decreased body weight gain in the 16 and 32 mg/kg; retarded weight gain occurred only in the second half of the study in the 8 mg/kg group.
Decreased urinary pH in the 8, 16, and 32 mg/kg/day groups; no biologically significant changes in urinalysis values between treated and control rats.
Lowered luteinizing hormone levels significantly to 3.3 ng/mL in the 32 mg/kg/day group; no significant changes in prolactin or testosterone levels were seen in any treated group.
Increased relative spleen, heart, and adrenal weights in all treated groups.
Increased relative brain weights.
Produced dosage- and time-dependent decreased conception rates during treatment.
Promoted significant fertility recovery within 5 weeks of drug withdrawal, with no significant differences between treated and control groups.
Increased incidence of epididymal degenerate cells in all groups.
Animal Model: Sprague-Dawley rats (female, 210 to 270 g) with reproductive dysfunction
Dosage: 10 mg/kg
Administration: p.o.; single dose or daily for 15, 16, 27 days
Result: Reduced hypothalamic dopamine, norepinephrine, and epinephrine.
Depleted hypothalamic dopamine, norepinephrine, and epinephrine.
Reduced uterus-cervix-vagina weights and caused vaginal mucosa attenuation with vacuolated surface epithelium, and caused splenic congestion.
Did not affect serum follicle-stimulating hormone, luteinizing hormone, and progesterone levels.
Induced partial ptosis and fecal softening as clinical signs.
Animal Model: Sprague-Dawley (Upj: TUC(SD)spf; male and female; 8-10 weeks of age, males 220-361 g, females 209-270 g at study start)
Dosage: 2; 4; 8 mg/kg
Administration: p.o.; daily
Result: Caused ptosis in all treated rats.
Increased mean body weight gain in treated females after 14 days of treatment.
Disrupted estrous cycles in treated females, with significantly more days in diestrus, fewer days in proestrus, estrus, metestrus, and fewer total cycles over 14 days of treatment.
Decreased conception rates dose-dependently.
Prolonged mean gestation lengths in treated females given 4 and 8 mg/kg.
Induced moderate to severe testicular tubular necrosis, spermatic giant cell formation, and tubular atrophy in treated males.
Caused exudative prostatitis and ampullary gland sperm granulomas in 2, 4, 8 mg/kg groups.
Delayed functional development.
Reduced negative geotaxis response scores and prolonged response times at multiple time points in treated groups.
Impaired reproductive ability of F1 offspring.
Animal Model: Long-Evans rats (adult male, 200-225 g)
Dosage: 2.5; 5; 10 mg/kg
Administration: i.p.; single dose
Result: Produced maximal depletion of dopamine and norepinephrine in the median eminence, intermediate lobe, and neural lobe.
Reduced dopamine concentrations in the striatum and nucleus accumbens.
Reduced dopamine levels in the dorsomedial nucleus.
Failed to reduce norepinephrine concentrations in the dorsomedial nucleus.
Caused no effect on 5-hydroxytryptamine concentrations in the dorsomedial nucleus.
Increased plasma prolactin and α-melanocyte-stimulating hormone levels.
Animal Model: Long-Evans (adult female, 200-225 g, regular estrous cycles prior to treatment)
Dosage: 2.5 mg/kg
Administration: i.p.; single dose; or daily for 12 days
Result: Caused rats to become acyclic with persistent diestrous-like smears by 6-7 days of chronic treatment.
Produced 80-90% dopamine depletion and 50-70% norepinephrine depletion in the median eminence, intermediate lobe, and neural lobe with both acute and chronic doses, with no tolerance development.
Caused greater dopamine depletion in the striatum with chronic administration than acute administration, with a nonsignificant trend toward greater depletion in the nucleus accumbens.
Produced modest decreases in dopamine and norepinephrine concentrations in the dorsomedial nucleus with both acute and chronic doses, with no effect on 5-hydroxytryptamine concentrations in this region.
性状 固体
颜色 Light yellow to light brown

化学信息

分子量 558.55
分子式 C27H22F4N4O3S
CAS No. 72141-57-2
别名 洛苏拉嗪

储存&溶解度

溶解度信息
DMSO: 7.31 mg/mL (13.09 mM), Sonication is recommended.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础